Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer

Medicine and Dentistry

• Bladder Cancer 100%
• Immune Disorder 100%
• Rapamycin 100%
• Mechanistic Target of Rapamycin 37%
• Neoplasm 25%
• Low Drug Dose 25%
• T Cell 25%
• T Cell Exhaustion 25%
• Metastatic Carcinoma 12%
• Drug Megadose 12%
• Prevalence 12%
• Mammalian Target of Rapamycin Complex 1 12%
• Malignant Neoplasm 12%
• Cystectomy 12%
• Cell Growth 12%
• Pharmacodynamics 12%
• Tumor Progression 12%
• Lung Metastasis 12%
• Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone) 12%
• Cell Metabolism 12%
• Cellular Immunity 12%
• Wound Complication 12%
• Mammalian Target of Rapamycin 12%
• Cancer Model 12%
• Cancer Immunotherapy 12%
• T Cell Activation 12%
• T Cell Differentiation 12%
• Programmed Death-Ligand 1 12%
• Bladder Tissue 12%
• Tumor 12%
• Oral 12%
• phosphorylation 12%
• Adverse Event 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Bladder Cancer 100%
• Rapamycin 100%
• Mammalian Target of Rapamycin 37%
• Neoplasm 25%
• Low Drug Dose 25%
• Pharmacodynamics 12%
• Adverse Event 12%
• Prevalence 12%
• Malignant Neoplasm 12%
• Tumor Growth 12%
• Cancer Model 12%
• Lung Metastasis 12%
• Immunotherapy 12%
• Wound Complication 12%
• Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone) 12%
• Mammalian Target of Rapamycin Complex 1 12%

Immunology and Microbiology

• Sirolimus 100%
• Immune System Disorders 100%
• Tumor Cell 18%
• Low Drug Dose 18%
• T Cell 18%
• Cell Growth 18%
• T Cell Exhaustion 18%
• Adoptive Immunity 9%
• Programmed Death-Ligand 1 9%
• Prevalence 9%
• Cell Metabolism 9%
• Cell Differentiation 9%
• Syngenic 9%
• Drug Megadose 9%
• Pharmacodynamics 9%
• Cancer Immunotherapy 9%
• phosphorylation 9%
• Bladder Tissue 9%
• Mammalian Target of Rapamycin Complex 1 9%